BACKGROUND: In a cross-sectional study examining late effects of pediatric sarcoma therapy, long-term survivors were evaluated on their activities of daily living (ADL) performance. PROCEDURE: Thirty-two persons with Ewing sarcoma family of tumors, rhabdomyosarcoma, and non-rhabdomysarcoma-soft tissue sarcoma enrolled an average of 17 years after treatment. Participants were evaluated using the Assessment of Motor and Process Skills (AMPS) 1, a standardized observational evaluation of ADL task performance. Means and 95% confidence intervals for ADL motor and ADL process ability measures were calculated for four groups: (1) sarcoma survivors, (2) "well" adults matched for age and gender, (3) "well" adults matched for gender that were 10 years older, and (4) "well" adults matched for gender that were 20 years older. RESULTS: ADL motor ability was significantly lower for sarcoma survivors than for the age- and gender-matched comparison group (P < 0.05). There was no significant difference between ADL motor ability of sarcoma survivors and the comparison group 10 years older, but sarcoma survivors had significantly better ADL motor ability (P < 0.05) than the oldest comparison group (20 years older). Sarcoma survivors had significantly worse ADL process ability than the age-matched group (P < 0.05). There was no difference in ADL process ability between the sarcoma survivors and comparison groups that were 10 and 20 years older. CONCLUSIONS: This first report of a clinical evaluation of ADL limitation in pediatric sarcoma survivors treated with intensive multimodal cancer therapy suggests that influences on performance of daily life activities are more common than previously reported.
BACKGROUND: In a cross-sectional study examining late effects of pediatric sarcoma therapy, long-term survivors were evaluated on their activities of daily living (ADL) performance. PROCEDURE: Thirty-two persons with Ewing sarcoma family of tumors, rhabdomyosarcoma, and non-rhabdomysarcoma-soft tissue sarcoma enrolled an average of 17 years after treatment. Participants were evaluated using the Assessment of Motor and Process Skills (AMPS) 1, a standardized observational evaluation of ADL task performance. Means and 95% confidence intervals for ADL motor and ADL process ability measures were calculated for four groups: (1) sarcoma survivors, (2) "well" adults matched for age and gender, (3) "well" adults matched for gender that were 10 years older, and (4) "well" adults matched for gender that were 20 years older. RESULTS: ADL motor ability was significantly lower for sarcoma survivors than for the age- and gender-matched comparison group (P < 0.05). There was no significant difference between ADL motor ability of sarcoma survivors and the comparison group 10 years older, but sarcoma survivors had significantly better ADL motor ability (P < 0.05) than the oldest comparison group (20 years older). Sarcoma survivors had significantly worse ADL process ability than the age-matched group (P < 0.05). There was no difference in ADL process ability between the sarcoma survivors and comparison groups that were 10 and 20 years older. CONCLUSIONS: This first report of a clinical evaluation of ADL limitation in pediatric sarcoma survivors treated with intensive multimodal cancer therapy suggests that influences on performance of daily life activities are more common than previously reported.
Authors: George F Wittenberg; Robert Chen; Kenji Ishii; Khalafalla O Bushara; Susan Eckloff; Earllaine Croarkin; Edward Taub; Lynn H Gerber; Mark Hallett; Leonardo G Cohen Journal: Neurorehabil Neural Repair Date: 2003-03 Impact factor: 3.919
Authors: Rajaram Nagarajan; Joseph P Neglia; Denis R Clohisy; Yutaka Yasui; Mark Greenberg; Melissa Hudson; Michael A Zevon; Jean M Tersak; Arthur Ablin; Leslie L Robison Journal: Cancer Date: 2003-05-15 Impact factor: 6.921
Authors: Marc Sampedro Pilegaard; Karen la Cour; Lisa Gregersen Oestergaard; Anna Thit Johnsen; Line Lindahl-Jacobsen; Inger Højris; Åse Brandt Journal: Palliat Med Date: 2018-01-04 Impact factor: 4.762
Authors: Gerhard M Hobusch; Thomas M Tiefenboeck; Janina Patsch; Christoph Krall; Gerold Holzer Journal: Clin Orthop Relat Res Date: 2016-02-16 Impact factor: 4.176
Authors: Å Brandt; M S Pilegaard; L G Oestergaard; L Lindahl-Jacobsen; J Sørensen; A T Johnsen; K la Cour Journal: BMC Palliat Care Date: 2016-01-22 Impact factor: 3.234